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The breast tumour microenvironment ʹ role in cancer development, 
progression and response to therapy 
 
Suruchi Mittal, Nicola J Brown and Ingunn Holen 
University of Sheffield UK 
 
 
 
Abstract:  
 
Introduction: Numerous clinical and pre-clinical studies have provided ample evidence supporting 
that the tumour microenvironment plays a significant role during breast cancer development, 
progression and in determining the therapeutic response.  
 
Areas covered: This review focuses on the evolving concept of the microenvironment as the critical 
participant in each step of the multi-stage process of malignant progression. Currently, only a small 
number of molecules form part of routine molecular diagnostics in breast caner, but 
microenvironment-derived biomarkers are potential additions to existing predictive and prognostic 
marker panels. We will discuss the dependency of the breast tumour cells on different components 
of the microenvironment for their survival, dissemination, dormancy and establishment in secondary 
sites to form overt metastasis, as well as the potential as a therapeutic target to improve breast 
cancer outcome.  
 
Expert commentary: Despite the importance in the development of breast cancer, the contribution 
of the microenvironment is not considered in routine diagnostic testing or informing therapeutic 
decisions. However, introduction of immunotherapy will increasingly require patient selection based 
on the stromal composition of the primary breast tumour. Better understanding of the role of 
specific microenvironment-derived molecules is likely to inform personalized therapy, leading to 
improved patient outcome. 
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1. Introduction: Despite the sequencing of the human genome and tremendous progress made in 
our understanding of cancer genetics and the molecular pathways involved in tumour development, 
cancer remains the leading cause of death. Breast cancer is the most frequently diagnosed cancer 
among women [1] and is still the prime cause of cancer-related death in women worldwide. 
Although organ-confined disease is mainly curable, metastatic and recurrent disease has poor 
prognosis with a 5-year survival of 22% [2]. Breast tumours display considerable cellular and 
molecular heterogeneity, including receptor status (ER, PR, and/or ERBB2/HER2), and recent 
molecular profiling has categorized breast cancer into at least six subtypes [3-8]. The intra-tumour 
heterogeneity present within a single biopsy is not only a challenge for accurate diagnosis/prognosis 
but also underpins the complexity of the dynamic and interconnected cellular states during 
metastatic progression [9].  This heterogeneity is not only due to the presence of different cancer cell 
clones; the content and composition of the tumour stroma also varies between different tumour 
areas. 
Pioneering experiments by the Bissell group showed that tumour epithelial cells can only thrive in an 
aberrant microenvironment composed of altered ECM and other non-transformed cells like 
fibroblasts, myofibroblasts, immune cells, myoepithelial cells and endothelial cells [10-13]. 
Subsequently it has been demonstrated that the gene expression signature of the breast tumour 
stroma can predict disease outcome, independent of the clinical and molecular tumour cell profile 
[14, 15]. In addition to prognostic information, a stromal signature has been reported that could 
predict tumour response to neoadjuvant treatment [16].  
The following sections summarises the role of the microenvironment in each stage of breast cancer 
development and progression, from primary tumour growth and local invasion through 
dissemination via the circulation and metastatic progression in distal sites. 
 
2. Defining the Tumour Microenvironment 
The tumour microenvironment encompasses the proliferating tumour cells along with a variety of 
non-cancerous cells (generally referred to as the stroma) present in the tumour. These include 
fibroblasts, immune cells, endothelial cells, infiltrating inflammatory cells, adipocytes as well as 
signalling molecules and extracellular matrix (ECM) components [17]. This is a constantly changing 
environment that unfolds with time and tumour progression, and may also vary between breast 
tumour types (e.g. basal vs luminal tumours). Stromal cells influence the behaviour of epithelial cells 
by secreting a range of ECM proteins, chemokines, cytokines and growth factors. The various 
proteins secreted by stromal cells can aberrantly activate autocrine and paracrine loops, which affect 
the cell behaviour in a paracrine or juxtacrine fashion. These interactions between stroma and 
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tumour cells, along with underlying genetic defects of the tumour cells, dictate the growth 
characteristics, morphology, and invasiveness of the tumour. In the context of this review we will 
describe each of the different environments that tumour cells encounter, highlighting key 
interactions suggested to regulate breast cancer progression.  
 
2.1 Context is everything: The role of the stroma in primary breast tumours  
As mentioned above, breast tumours comprise a community of epithelial-derived cancer cells 
supported by a variety of stromal components, often collectively referred to as ͚ƚŚĞ tumour 
ŵŝĐƌŽĞŶǀŝƌŽŶŵĞŶƚ͛ (Figure 1). The composition of the breast stroma is shown to influence breast 
density, which in turn plays a role in the development of tumours. Mammographic breast density 
measures the scale of radiodense fibroglandular tissue present in the breast, reflecting the relative 
amounts of various tissue elements, and is used as a predictor of breast cancer risk [18-24]. 
Increased mammographic breast density corresponds to higher fractions of stroma and epithelium as 
compared to adipose tissue [25]. Women with mammographically dense breasts have a 2 to 6-fold 
increase in their susceptibility to develop breast cancer, highlighting the link between the stroma and 
tumour progression [26, 27]. This is further supported by studies showing that tumours most often 
arise within the densest parts of the heterogeneous breast environment. [22, 28]. The IBIS-1 trial 
demonstrated that women treated with tamoxifen for 5 years who had a at least a 10% reduction in 
breast density had a 63% reduction in risk of breast cancer, whereas women who did not have 
reduced breast density had no reduction in breast cancer risk [29]. These results is a key example of 
how therapy-mediated alterations of the microenvironment affects subsequent breast tumour 
development. 
 
2.2 Tumour Infiltrating Lymphocytes 
Breast tumours are not generally considered to be immunogenic and hence having limited response 
to immunotherapy, but recent reports describe subset of breast cancers with a rich immune 
microenvironment [30]. Tumour infiltrating lymphocytes (TILs) are the most common mononuclear 
immune infiltrates, with TILs composed of mainly T cells reported in majority of breast cancer 
patients [31, 32]. High TIL counts have been associated with an improved clinical outcome, especially 
in patients with triple negative breast cancer [33, 34, 35]. TIL count has also been linked with better 
survival in patients with ER negative tumours [31, 36]. Retrospective studies have indicated the 
usefulness of TILS as a prognostic marker; showing that higher number of TILs was associated with 
improved prognosis or better response to treatment [37]. It was recently demonstrated that a high 
CD8(+) TIL and a high CD8/FOXP3 ratio in residual tumours following neoadjuvant chemotherapy can 
4 
 
accurately predict improved prognosis in TNBC patients [38]. Similarly, the CD8+/FOXP3+ TIL ratio 
(CFR) might be a useful biomarker to predict treatment response to neoadjuvant therapy in 
aggressive breast cancer subtypes, such as TNBC and HER2 breast cancer patients [39]. Although 
numerous studies have demonstrated the effectiveness of TILs as a prognostic factor, additional 
prospective clinical studies are needed to clarify their utility in routine clinical practice. This is of 
particular importance in selecting subsets of patients who have tumours that may respond better to 
the increasing numbers of immunotherapeutic agents, used alone or as part of combination therapy. 
 
2.3 T regulatory cells (Tregs) 
Regulatory T cells (Tregs) can suppress effector T cell responses as well as the activity of other 
immune cells, acting as key mediators of peripheral tolerance preventing undesirable immune 
responses. Increased presence of Tregs in breast tumor biopsies has been linked with an invasive 
phenotype and diminished relapse-free and overall survival [40, 41, 42]. Transient ablation of Tregs 
leads to significant reductions in primary and metastatic tumor growth in a poorly immunogenic, 
oncogene-driven model of mammary carcinoma [43]. A recent study addressed the role of tumor 
microenvironment in regulating the distinct transcriptional and functional characteristics of Tregs by 
analysing their features in untreated human breast carcinomas, normal mammary glands and 
peripheral blood [44]. Tumor-resident Treg cells were found to be potentially tumour suppressive as 
they had a similar gene expression pattern to Tregs isolated from normal breast tissue. This did 
however not resemble the expression profile of activated peripheral blood Treg cells. Claudin-low 
breast cancers are reported to be highly enriched with Tregs as compared to other subtypes. Tregs in 
the microenvironment had higher expression of PD-1 and their recruitment was partly through 
tumor-generated chemokine CXCL12 [45]. The authors provided evidence that recruitment of Tregs 
to the tumor microenvironment restrained an effective antitumor response. They propose early Treg 
recruitment as a possible mechanism for the lack of response to immune checkpoint blockade 
antibodies in specific subtypes of cancer that are heavily infiltrated with adaptive immune cells [45].  
A Meta analysis of 10,259 patients showed that high Foxp3+ Tregs infiltration is associated with poor 
recurrence free survival in breast cancer patients [46]. Patients who had high numbers of 
intratumoral tumor-infiltrating Tregs before chemotherapy had a significantly shorter overall survival 
compared to patients with low Treg infiltrates [47]. On the other it was also reported that presence 
of Tregs surrounding the tumor, but not within the tumor itself, is associated with a higher risk of 
relapse and death [48]. Collectively Treg infiltration may have profound effects on the prognosis of 
breast cancer patients. 
 
5 
 
2.4 Neutrophils 
Neutrophils are white blood cells derived from bone marrow myeloid precursors, responsible for 
elimination of invading microorganisms and the most common leukocyte type in the blood stream. 
Neutrophils can either promote or inhibit tumourgenesis, depending on the relative concentration of 
cytokines in the microenvironment. They can be functionally polarized in response to stimulatory or 
inhibitory factors rendering them protumourigenic [49] or antimetastatic [50]. A protumourigenic 
role was shown when neutrophils associated with primary tumour promoted tumour growth by 
producing factors which stimulated the tumour vasculature [51]. Using murine mammary tumour 
models it was reported that primary tumour can activate specific neutrophils known as tumour 
entrained neutrophils ͞dEƐ͟ that have unique capacity to inhibit metastatic seeding in the lung [50]. 
This was the first report which demonstrated an antimetastatic role for selected subsets of 
neutrophils. 
The neutrophil to lymphocyte ratio is a good indicator of the degree of inflammation, which plays an 
important role in tumour progression and metastasis. Meta-analyses of 12 and 8 studies involving 
7951 and 4293 breast cancer patients, respectively, demonstrated that patients with higher 
neutrophil-to-lymphocyte ratio (NLR) had poorer prognoses than those with low NLR [52, 53]. A 
further meta-analysis of 15 studies comprising a total of 8563 patients concluded that higher NLR is 
linked with adverse overall survival (OS) and disease free survival (DFS). A high NLR was particularly 
prognostic for reduced DFS in patients with ER-negative and HER2-negative breast cancer subtypes 
[54]. Similar reports have shown a significant association between elevated NLR and increased 
mortality in breast cancer patients in all subtypes [55].  
Neutrophils are potent suppressors of T-cell activation; the link between neutrophils and suppression 
of NK-cell activity was recently established showing that neutrophils were responsible for reduced 
NK-cell function, which in turn increased the intraluminal tumour cell survival time and facilitated 
metastasis [56]. The study used YAC-1 cells (well known targets of NK-cell clearance) and injected 
them intravenously into mice bearing 4T1 tumours, the number of cells that retained in the lungs of 
these mice after 4 hours were eightfold higher than that of those injected into naïve controls. In 
contrast, when 4T1 tumour bearing mice were depleted of neutrophils prior to YAC-1 injection, the 
number of tumour cells were retained to the same levels as in the naïve mice, suggesting that 
neutrophils were facilitating this retention by disrupting NK cell-mediated clearance [56]. Studies in 
model systems reported the role of neutrophils extracellular traps (NETs, a mechanism by which 
neutrophils capture and kill bacteria) in promoting cancer. The study found that 4T1 mammary 
tumours generate neutrophils that are predisposed to the formation of NETs, and that this 
phenomenon increases with advance in tumour stage [57]. Another report demonstrated that 
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metastatic breast cancer cells can induce neutrophils to form NETs after they arrive in the lungs of 
mice by using intravital imaging. They also documented the presence of NETs in clinical samples of 
the aggressive triple-negative subtype of human breast cancer [58].  
 
 
2.5 Macrophages  
Macrophages are members of mononuclear phagocyte system; they represent the most abundant 
leukocyte population in breast tumours and are suggested to be involved at each stage of cancer 
progression. Macrophages can differentiate into spectrum of discrete and functional phenotypes, 
which is regulated via signals from the microenvironment. Although macrophage populations are 
associated with plasticity and have overlapping markers, they are often broadly categorised as M1 
(tumour inhibitory) and M2 (tumour-promoting). M1, classically activated, macrophages express a 
wide range of pro-inflammatory genes. Alternatively activated (M2) macrophages are induced by 
type 2 cytokines and express high levels of anti-inflammatory genes. Increased M1 macrophages are 
found within the tumour microenvironment where annexin 1 (ANXA1) is the immumodulatory 
protein responsible for macrophage polarization and interaction [59]. M2 macrophages are shown to 
secrete CHI3L1, which promoted the metastasis of breast cancer cells both in vitro and in vivo [60]. A 
recent study reported that epithelial to mesenchymal plasticity in breast cancer cells is regulated by 
macrophage subtypes; M2 macrophages may confer tumour outgrowth whereas the M1 
macrophages contribute to dormancy of metastatic breast cancer cells [61].  
Several studies have reported a correlation between macrophage subtype, location and density in 
determining the survival of breast cancer patients [62, 63]. The density of tumour-associated 
macrophages (TAMs) has been linked to hormone status, lymph node metastasis and is ultimately 
related to invasive disease and poor prognosis [64-67].  CD68+ TAMs in tumour stroma is associated 
with worse prognosis in human breast cancer [68]. CD68 positive macrophages are found to 
accumulate in the normal tissue surrounding breast cancer lesions and mesenchymal stem cells and 
macrophages interact through IL-6 to promote inflammatory breast cancer [69]. TAMs have also 
been shown to produce matrix-degrading enzymes, potentially facilitating tumour cell dissemination 
and spread [70, 71]. Various cytokines released by TAMs play a critical role in mediating angiogenesis 
and invasion of cancer cells [72]. Studies in murine models of spontaneous breast cancers have 
demonstrated that macrophages are intimately involved in seeding and persistent growth of tumour 
cells at metastatic sites [73]. The study identified a population of host macrophages exhibiting a 
distinct phenotype characterized by a specific cell surface marker signature (F4/80+CSF-
1R+CD11b+Gr1-CX3CR1highCCR2high and VEGFR1high) that is recruited to extravasating pulmonary 
metastatic cells. Ablation of this population showed that these macrophages are essential for 
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efficient metastatic seeding and  growth [73]. Recently it was demonstrated that CCR2 acts as a 
functional signalling receptor capable of triggering a prometastatic chemokine cascade involving 
macrophage production of CCL3 [74]. Collectively, tumour associated macrophages facilitate 
neoplastic transformation, tumour immune evasion and support the metastatic cascade, however 
therapeutic targeting is likely to require tailoring to specific subsets. 
 
2.6 Endothelial cells and angiogenesis 
Endothelial cells, which form the lining of tumour blood vessels, are a major component of the 
tumour microenvironment stromal compartment, and are central to the process of tumour 
angiogenesis [75]. This hallmark of cancer is critical for the development and progression of primary 
breast cancer ensuring a constant supply of oxygen and nutrients, is permissive for extravasation of 
tumour cells into the systemic circulation, intravasation into the secondary or distal site and is a 
prerequisite for successful metastatic growth. The multistep process of angiogenesis is regulated by a 
plethora of growth factors, cytokines and oxygen sensing (hypoxia), with one of the key molecules 
being vascular endothelial growth factor (VEGF) which is regulated in part by the hypoxic 
microenvironment [76]. However tumour vessels are abnormal, have a disorganised structure, are 
often leaky and immature, lacking the recruitment of perivascular cells (pericytes) required for 
vascular maturation. This characteristic of tumour vessels can result in enhanced sensitivity to 
radiation and chemotherapy, suggesting that pericytes may promote therapeutic resistance. In solid 
cancers including breast, tumour microvascular density (MVD) a surrogate marker of angiogenesis is 
inversely correlated with patient survival irrespective of other prognostic factors and tumour hypoxia 
is positively associated with tumour cell invasion and metastasis [77]. Despite the promising 
preclinical studies demonstrating the efficacy of anti-angiogenic therapies, this has not translated to 
the clinical setting in breast cancer. Positive responses were initially reported before resistance to 
treatment [78] and significant cardiovascular toxicities were demonstrated, resulting in the closure of 
a number of trials. Although a number of potential therapeutic targets have been identified in 
preclinical studies including ephrins, neuropilins [79], Notch/Jagged [80] hypoxia and metabolism, 
current clinical strategies for breast cancer include the use of predominantly bevacizumab an anti-
VEGF-A therapy in metronomic regimes or in combination with other chemotherapeutic regimes in 
specific breast cancer subtypes.  
 
2.7 Cancer associated fibroblast  
Cancer associated fibroblasts (CAFs) are the most abundant stomal cell types present in primary 
tumours. Although normal fibroblasts and CAFs appear to have a very similar phenotype, differences 
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in mRNA and protein expression have been reported [81, 82]. A number of markers of fibroblasts 
have been identified, but none are specific for CAFs, hampering their identification in tumours. CAFs 
have been shown to express ɲ-SMA, p53, podoplanin, CD10, fibroblast activation protein (FAP), 
matrix metalloproteinases (MMPs), tenascin-C and platelet-derived growth factor ;W'&ZɲͬɴͿ and 
loss of caveolin-1 (Cav-1) expression [83]. Despite their prevalence in the tumour microenvironment, 
their origin has not been conclusively determined, and emergence both from resident fibroblast and 
from bone marrow derived mesenchymal stem cells is reported [84-87]. Breast cancer-associated 
fibroblasts have been demonstrated to aid tumourigenic progression of both pre-malignant as well 
malignant epithelial cells [88-90]. By secreting growth factors (including FGFs, HGF, TGF-ɴ and SDF-1) 
breast cancer-associated fibroblast promote tumour cell proliferation [91-95]. Cytokines secreted by 
fibroblasts also contribute to proliferation, angiogenesis, invasiveness and direct tumour growth [96-
99]. Mechanistically it is not yet clear whether these secreted factors are the consequence of the 
cancer cells modulating the CAFs, or whether they are initiated prior to malignant transformation. 
Recent data have suggested a role of breast cancer associated fibroblast in inducing epithelial to 
mesenchymal transitions [100, 102]. Tumour suppressive effects of breast cancer associated 
fibroblasts have also been reported. It was demonstrated that tumourigenic potential of breast 
cancer cells is regulated by an interaction between Robo1 receptor and its ligand Slit2, which is 
secreted by stromal fibroblasts. Specific stromal fibroblast expressing Slit2 can prevent Robo1 
expressing cancer cell from progression [103]. Another study investigated the role of Tiam1 in 
tumour-associated fibroblasts on epithelial cell invasiveness using retroviral delivery of short hairpin 
RNA to suppress Tiam1 levels in three different experimental models. Tiam 1 silencing in dermal 
fibroblasts led to increased invasiveness of epidermal keratinocytes and in mice model of human 
breast cancer, co-implantation of mammary fibroblasts inhibited tumour invasion. These results 
indicate that Tiam1 in tumour associated fibroblast might have a role in regulating the effects of the 
tumour microenvironment on malignant cell invasion and metastasis [104].  
 
Several studies have reported that breast cancer-associated fibroblasts may contribute to therapy 
resistance [105-108]. The ability of ER-ɲ+ tamoxifen-sensitive premalignant and ER-ɲ+ tamoxifen-
resistant breast cancer cells to interact with breast tumour-derived fibroblasts was investigated using 
contact-dependent 3D co-culture systems, showing a direct involvement of breast tumour fibroblasts 
in loss of hormone sensitivity and acquisition of endocrine resistance [105]. G-protein-coupled 
receptor (GPER) was shown to be expressed in the stromal fibroblasts of primary breast cancer 
tissues and cancer associated fibroblasts (CAFs) isolated from tumour tissues. There results 
concluded that GPER mediates CAF-dependent tamoxifen resistance in breast cancer [106]. Similarly 
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tamoxifen resistance was induced by CAFs in a co-culture model of ER+ MCF7 cells with fibroblasts 
and CAFs also protect MCF7 cells against apoptosis induced by other anticancer agents [107]. 
Addition of conditioned medium (CM) from activated breast cancer associated fibroblasts is found to  
cause increased resistance of  MDA-MB-231 breast cancer to doxorubicin treatment [108]. 
Successful therapeutic targeting of CAFs therefore has the potential to affect a number of key 
processes associated with breast cancer development, however this will require better 
understanding of the precise role of different CAF subsets and the identification of differential 
markers of these populations. 
 
2.8 Adipocytes  
Presently the nature of interplay between adipocytes and cancer cells remains largely unknown, 
however recent investigations in the field indicate that the adipocyte occupies a important place in 
breast cancer progression. This lack of information about their role was mainly due to the fact that 
adipocytes disappear rapidly via the desmoplastic response of connective tissues during the early 
invasive steps, hence histological sections of breast tumour biopsies show very few adipocytes and 
are mostly totally devoid of them [109]. Reports have shown the dynamic desmoplastic events 
involving adipocytes in the histological sections of human breast carcinoma at the tumour invasive 
front located at the periphery of primary tumours [110, 111]. This tumour area is devoid of fully 
constituted stroma and exhibits a high ratio of adipocytes to fibroblasts. The cancer associated 
adipocytes (CAA) located at the interface exhibit reduce size and the center of the same tumour 
showed accumulation of fibroblast/fibroblast-like cells (CAFs), and adipocytes are no longer present 
[110, 111]. This size reduction of adipocytes implies lipolysis and tumour progression might depend 
on the CAA ͞ĂĐƚŝǀĂƚŝŽŶ͟ induced by invading cancer cell stimuli. Recent clinical studies have 
evaluated the prognostic importance of local adipose tissue invasion by cancer cells at the tumour 
margin, with the majority showing a positive correlation between adiposity and poor patient 
outcome [112-113]. The co-cultivation of human breast cancer cells with mature adipocytes led to 
increased invasive capacities both in vitro and in vivo [111]. The authors also show co-cultivated 
adipocytes generally exhibit a loss of lipid content, a decrease in late adipose markers, and 
overexpression of inflammatory cytokines and proteases. Therefore the CAA modified cancer cell 
characteristics and lead to a more aggressive phenotype. Breast cancer associated adipose tissue 
from freshly isolated tumours promote F-actin remodeling, cellular scattering, invasiveness, and 
spheroid reorganization of cultured breast cancer cells [114]. The authors identified paracrine 
secretion of oncostatin M (OSM) by cancer-associated adipose tissue which stimulated breast cancer 
progression. In addition, adipokines like adiponectin has been shown to stimulate the growth and 
10 
 
survival of breast tumour cells [115, 116]. Obesity, where in the normal balance of adipose tissue 
secretory proteins is disturbed, is identified as a negative prognostic factor for breast cancer [117, 
118] independent of menopausal status, tumour stage, and tumour hormoneʹbinding characteristics 
[119, 120]. Clinical studies have indicated that obese women exhibit at diagnosis an increase in 
lymph nodes involvement and a higher propensity to distant metastasis [121, 122].  
 
2.9 Myeloid-derived suppressor cells (MDSCs)  
MDSCs are a heterogeneous group of immature myeloid cells, which inhibit innate and adaptive 
immunity. It has been shown that levels of MDSCs correlates with the clinical stage and metastatic 
burden of disease in breast cancer patients. Through calculating the percentage of whole blood 
MDSCs by flow cytometry, increased levels of these cells were found in patients with later stage 
disease [123]. Similarly, a study of 25 patients with metastatic breast cancer demonstrated that 
those with higher than average levels of peripheral blood MDSCs following palliative systemic 
therapy had a shorter overall survival [124]. It has also been reported that high frequencies of MDSCs 
correlates with increased rate of recurrence and metastasis of breast cancer, with patients having 
significant enrichment of circulating monocytic-MDSCs (Mo-MDSCs). Presence of Mo-MDSCs 
correlated with disease severity, increased metastasis to lymph nodes and visceral organs [125]. In 
contrast, breast cancer patients with lower levels of circulating MDSCs have a higher possibility of 
achieving a pathological complete response (pCR) [126]. The mechanism underlying MDSCs-
mediated immunosuppression is not well understood and a recent study identified a poorly 
differentiated subset of MDSCs in breast cancer patients, which suppresses T-cell functions through 
STAT3-dependent indoleamine 2,3-dioxygenase (IDO) upregulation [127]. MDSCs can impair 
antitumor immunity and therefore have emerged as a significant barrier to cancer therapy, a report 
provided the first evidence of a critical role for interferon regulatory factorʹ8 (IRF-8) expressions in 
the transcriptional regulation of MDSC subset development. Levels of IRF-8 in MDSCs of breast 
cancer patients declined with increasing MDSC frequency, implicating IRF-8 as a negative regulator in 
human MDSC biology. The authors suggest that this mechanism may provide new avenues to target 
MDSCs [128]. MDSCs have been identified to undergo direct osteoclast differentiation thereby 
promoting enhanced bone destruction and tumour growth. MDSCs isolated from mice with bone 
metastasis were shown to differentiate into functional bone-resorbing osteoclasts in vitro and in 
vivo. These results indicate that MDSCs are primed to be osteoclast progenitors (OCP) and the bone 
microenvironment in-vivo triggers their differentiation into functional osteoclasts [129]. Tumour-
infiltrating MDSCs (tiMDSCs) were recently identified as the responsible cells for the distal 
colonization of breast cancer cells in the lung of murine orthotropic breast tumour models. 
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Furthermore tiMDSCs preferentially locate to hypoxic areas and produce higher levels of pro-
inflammatory factors and lower levels of anti-inflammatory factors [130]. Taken together targeting 
MDSCs actions may improve therapeutic outcomes. 
 
2.10 Extracellular Matrix (ECM)  
The tumour microenvironment comprises a rich ECM, a complex molecular network of components 
including collagens, fibronectin, laminins, glycoproteins and polysaccharides with different physical 
and biochemical properties [131, 132]. The ECM of the breast is described to provide the guiding 
force which regulates various stages of breast development and differentiation [133] and remodeling 
of the ECM composition can lead to alterations in the function and structure of organs [134, 135]. 
The ECM becomes progressively stiffer and more collagen- rich during tumour progression, a process 
called desmoplasia [136]. This is associated with increased collagen fibre linearization and thickening 
as a result of deposition and cross-linking of the collagen [137], the orientation of the collagen fibres 
is also significantly alerted [138]. Tumour cells respond to the mechanical changes in the ECM 
through mechanosignalling [139]. Mechanical changes and ECM stiffness leads to upregulation and 
clustering of integrins, and aid in tumour initiation as well as maintenance of proliferative capacity of 
late-stage tumour cells [140]. Increasing breast stiffness upregulates oncogenic microRNAs and 
various proliferative/invasive pathways implicated in breast cancer [141-143]. In model systems, 
ECM rigidity modulates the nature and number of immune infiltrates [144]. MMTV-PyVT tumours 
arising in a dense collagen microenvironment have increased cytokine expression as compared to 
tumours arising in a non-dense microenvironment. GM-CSF, PGDF-BB and IL-ϭɲ , factors involved in 
neutrophil maturation and recruitment were increased in dense-collagen tumours. The collagen-
dense tumour microenvironment can act as the deciding factor between a tumour promoting and 
tumour suppressing phenotype of neutrophils. Depletion of neutrophils significantly slowed the 
formation of new tumours and reduced lung metastases only in tumours arising in the collagen 
dense tumour microenvironment, but not in the wild type MMTV-PyVT mice. These results indicate 
that tumour progression in a collagen-dense microenvironment, compared to non-dense 
microenvironments, occurs through a distinct subpopulation of immune cell effectors [144]. Tumour 
growth and invasion requires formation of new blood vessels and there is an intimate link between 
ECM rigidity and vascular remodelling [145]. Studies have shown that vascular density is significantly 
higher in invasive ductal carcinoma in situ (DCIS) as compared to low grade DCIS [146] and that blood 
vessels within the tumour core are stiffer and thinner compared to those at the invasive front [147]. 
Endothelial permeability and leukocyte transmigration, which potentially mediates tumour 
progression and invasion, is also a consequence of increased ECM stiffness [148]. Recent studies 
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using model systems have suggested a role of ECM in creating tumour-hospitable pre-metastatic 
niches. The collagen cross-linking protein lysyl oxidase (LOX) has been shown to regulate invasion; 
high levels of LOX in primary breast tumours or systemic delivery of LOX leads to osteolytic skeletal 
lesion formation that was abrogated when LOX was genetically silenced [149].  
The biophysical properties of the ECM can also influence treatment outcome in breast cancer 
patients. Patients with softer breast tumour were found to be more responsive to neoadjuvant 
chemotherapy as compared to those with stiffer tumours [150]. Breast elastography (EG) was used 
to evaluate tumour stiffness and patients in the low EG group had significantly higher clinical 
complete response to neoadjuvant chemotherapy than the patients in the high EG group [150]. 
Cancer cell-ECM interactions perpetuate chemoresistance [151]. It has also been shown that hypoxia 
and stiff breast tumours stimulate proliferation of breast cancer stem-like cells [152]. Taken 
together, the evidence indicates that a stiffer ECM represents a tumour growth permissive 
environment, associated with therapeutic resistance and supporting tumour cell proliferation, 
invasion, vasculogenesis, and pro-oncogenic immune infiltration.  
 
3. The pre-metastatic Niche: Preparing for the future  
An epidemiological study of more than 12,000 breast cancer patients demonstrated that metastasis 
might be initiated already 5ʹ7 years before the diagnosis of the primary tumour [153]. Recent 
evidence supports that metastatic dissemination often occurs early during tumour formation, 
challenging the concept that late disseminated cancer cells possess higher ability to form metastases, 
and instead reported that mouse and human mammary cancer cells migrate and disseminate from 
morphologically very early lesions [154]. The history of cancer cell dissemination goes back to the 
pivotal discovery by Stephen Paget that hypothesized metastasis relies on interactions between 
͞ƐĞĞĚƐ-the cancer ĐĞůůƐ͟ and the ͞ƐŽŝů-the host ŵŝĐƌŽĞŶǀŝƌŽŶŵĞŶƚ͟ [155]. In line with this theory 
Isaiah Fidler demonstrated that metastatic colonization could occur only at certain organ sites [156]. 
Subsequent studies have revealed that tumours can induce formation of microenvironments in 
distant organs which are conducive to their survival and outgrowth before their actual arrival to 
these sites [157-160]. These preordained microenvironments are termed as ͚ƉƌĞ-metastatic ŶŝĐŚĞƐ͛ 
(PMNs). The majority of the work exploring the tumour-directed PMN formation has used 
orthotropic and transgenic mouse models of metastasis and most of it is based on lung metastasis 
[161-162]. Increasing clinical evidence to support the existence of PMNs in tissue samples from 
cancer patients has been observed in sentinel lymph nodes from patients with colorectal, prostate, 
breast, thyroid, bladder, gastric and renal cell carcinomas [159]. Breast cancer cells also display a 
propensity to metastasize to particular locations such as bone, liver and brain [163-165]. Pre-
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metastatic niche is the result of cooperative systemic effects of tumour-secreted factors [166] and 
tumour- shed extracellular vesicles (EVs), which create a temporal sequence of events and lead to 
the evolution of future metastatic sites.  Adhesion and ECM molecules like integrins and tenacin 
expressed by primary tumour cells have been shown to promote dissemination of cancer cells [167-
169]. Exosomes were isolated from organotropic human breast and pancreatic cancer cell lines that 
metastasize primarily to the lung, liver or both sites, labelled and injected into nude mice. ϮϰരŚ after 
injection, exosome biodistribution and uptake was quantified in distant organs. Organ specificity of 
exosome biodistribution matched the organotropic distribution of the cell line of origin in both 
immune-compromised and immune-competent models. Therefore, tumour derived exosomes lead 
to the formation of a favourable pre-metastatic microenvironment; the same study also identified 
determinants of exosome-mediated organ specific conditioning, capable of redirecting metastasis to 
other sites [170]. Exosomes contain MMPs, inflammatory cytokines and activated growth factor 
receptors that may affect breast cancer progression to metastatic disease [171, 172]. Extracellular 
vesicles (EVs) derived from brain metastatic breast cancer cells are capable of breaching the blood 
brain barrier (BBB) and promote extravasation of cancer cells through the BBB [173].  
Taken together, there is accumulating experimental evidence supporting that tumour-derived 
circulating exosomes and EVs might provide information not only to predict the metastatic 
propensity, but also to indicate the organ sites of future metastasis. Whether the pre-metastatic 
niche concept identified in model systems also holds true for human disease remains to be firmly 
established. 
 
4. Entering the circulation: a struggle for survival  
In order for tumour cells to escape from primary tumours and initiate the metastatic cascade, they 
undergo a process called epithelial-to-mesenchymal transition (EMT) [76, 174-176]. During EMT, 
cancer cells reduce expression of E-cadherin and increase MMP expression, accompanied by changes 
in a set of pleiotropically acting transcriptional factors orchestration the EMT process and the 
migratory potential of cancer cells [76]. As illustrated in figure 2, tumour cells then leave the original 
environment to which they are adapted and enter the blood stream, becoming circulating tumour 
cells (CTCs) [177]. The majority of CTCs die as a result of this shear stress and/or anoikis, loss of 
adhesion to extracellular matrix and immunological attack, hence only a fraction manage to 
extravasate at distant sites where they may persist as disseminated tumour cells (DTCs) [178, 179]. 
Direct interactions with platelets provide a shield to tumour cells, resulting in activation of the TGF-ɴ 
signaling pathway, which promotes metastasis, and invasion by inducing EMT and 
immunosuppression [174, 180]. An increase in circulating platelet count has been associated with a 
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poorer prognosis in breast cancer patients, suggesting a potential direct role in the pathogenesis of 
this disease [181, 182]. B-thromboglobulin and P-selection are two markers of platelet activation, 
which are increased in breast cancer patients [183, 184]. One mechanism by which platelets get 
activated is tumour cell-induced platelet aggregation (TCIPA), and the ability of tumour cells to 
induce platelet aggregation correlates with their metastatic potential [185, 186]. TCIPA can occur 
either by direct contact with the tumour cells or by different mediators like ADP, thromboxane A2, or 
serine proteinases, including thrombi [187-190]. Once platelets are activated, they release various 
factors that promote metastasis by increasing the survival capacity of cancer cells within the 
circulation and facilitate adhesion to the endothelium, extravasation, and finally the growth of 
tumour cells at the metastatic site [191-194]. Exposed collagen IV on tumour blood vessels has been 
shown to facilitate platelet recruitment in the tumour microenvironment and is considered as a 
marker for angiogenesis in breast cancer [195]. Autotaxin (ATX) which is stored in ɲ-granules of 
resting human platelets is released upon tumour cell-induced platelet aggregation leading to the 
production of lysophosphatidic acid (LPA), promoting skeletal metastasis of breast cancer [196]. 
Overall the microenvironment is considered key in many of the processes involved in regulating 
tumour cell dormancy and subsequent escape and disease progression. 
  
5. The Microenvironment and Cancer Cell Dormancy 
Breast cancer is associated with a dormant asymptomatic phase that can last for up to 25 years [197, 
198] followed by a relapse, however this varies between subtypes. Patients with HER2+ or TNBC 
subtype experience earlier relapse (<5 years from surgery) to lung, brain or liver, in contrast to 
patients with ER+ tumours which exhibit constant rate of relapse over several years and tend to 
predominantly metastasize to bone [199, 200]. Dormancy can be divided into three broad categories: 
cellular dormancy, angiogenic dormancy and immune-mediated dormancy [201]. Arrival in a new 
microenvironment poses a challenge to the tumour cells for growth and proliferation, resulting in 
cellular dormancy [201, 202]. A limited supply of nutrients and oxygen may lead to angiogenic 
dormancy, where tumour cells are able to proliferate to form micrometastatic lesions but require 
further stimulation through angiogenesis (angiogenic switch triggered locally or systemically) for 
their continued growth and progression to macrometastatic disease [203-205]. Immune dormancy 
describes the state where tumour cells are not eliminated but their outgrowth is limited by the 
resident immune cells [206]. Precisely how dormancy is maintained and subsequent escape triggered 
remains to be established, but several reports have shown a reduction in PI3K-AKT signaling 
associated with dormancy like phenotypes and might also be responsible for the quiescence of the 
disseminated tumour cells [207-209]. 
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6. Metastatic progression: The final battle  
Tumour cell survival at a distal site relies on successful extravasation, invasion, and establishment of 
cell-cell and cell-matrix interactions in the metastatic niche (Figure 3). Most disseminated cancer 
cells are likely to be poorly adapted to the microenvironment of the tissue in which they have 
arrived; only a small percentage of the cells that survive are capable of reinitiating growth in distant 
organs and have been termed as metastatic stem cells (MetSCs) [210-212]. Successful metastatic 
dissemination requires not only that cancer cells home to distal sites but also that they locate to 
specific environments termed ͞ŵĞƚĂƐƚĂƚŝĐ ŶŝĐŚĞƐ͞ in which interactions between tumour cells and 
the local microenvironment supports their survival and further growth. It is not yet known if 
metastatic niches exist in all organs, or whether the bone marrow serves as a reservoir for future 
dissemination once the tumour starts to progress due to its specialist niche environments that 
support hematopoietic stem cells (HSCs). However, the composition of the microenvironment differs 
significantly between lung, liver, brain and bone, hence tumour cells must adapt to vastly different 
new sites in order to successfully colonise different organs. Due to difficulties in accessing internal 
organs for studies of tumour cell dissemination, our knowledge of the processes involved comes 
largely from bone marrow samples (possible in the clinical setting) or from in vivo model systems.  
 
6.1  Homing to bone 
Bone is the most common site of metastasis in breast with median survival of around 2-3 years 
following initial diagnosis of skeletal involvement. It has been hypothesized that tumour compete for 
space the HSC niche located in the bone marrow, and once within this niche, they can be stimulated 
to proliferate [213-215]. In support of this, it has been demonstrated that increased expression of 
fibronectin allows tumour cells to adhere to the HSC [216, 217] and that the osteogenic niche 
supports metastasis of breast cancer cells to the bone [166, 218]. DTCs may remain dormant 
indefinitely, but in a proportion of patients they switch to a proliferative phenotype, causing 
increased osteoclast-mediated bone resorption ultimately resulting in osteolytic lesions associated 
with pain and skeletal complications. Why breast cancer cells preferentially home to bone is not fully 
understood, nor is it clear to what extent the bone marrow act as a reservoir of tumour cells for 
further dissemination to other organs. It is proposed that breast cancer cells can express molecules 
normally found in bone, a process called osteomimicry, facilitating their homing to and colonisation 
of the bone microenvironment [219]. As an example, CXCR4 has been shown to specifically aid in 
bone metastasis by stimulating tumour cell recruitment in response to its interaction with 
CXCL12/SDF-1a ligand [220]. However, expression of CXCR4 is not a universal feature bone 
metastasis, as the bone homing clones of MDA-MB-231 breast cancer cells do not express this 
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molecule [213, 214]. Evidence from model systems suggests that increased bone turnover caused by 
ovariectomy (mimicking post-menopausal bone) triggers proliferation of dormant breast cancer cells 
to form overt metastasis [221]. Crosstalk with cells of the bone environment then initiates a vicious 
cycle of tumour proliferation and bone destruction [222, 223]. Proliferating tumour cells secrete 
factors like parathyroid hormone-related protein (PTHrP), interleukins (IL-8, -11), MMP-1, 
cyclooxygenase-2 (COX-2), transcription factor GLI2 and HIF-ϭɲ that promote both the growth of 
tumour cells in bone marrow and also contribute to osteolysis. Osteoclast-mediated bone 
destruction in turn leads to the release of pro-tumourigenic growth factors (e.g. TGF-ɴ), which are 
otherwise stored in latent form [224, 225]. Although the presence of elevated bone turnover 
markers like CTX in patient serum is used to support a diagnosis of skeletal metastasis, there are no 
biomarkers of early dissemination in bone available for clinical use, hence bone metastases are 
frequently not detected until they become symptomatic [226]. 
 
6.2  Homing to other organs 
As discussed in the earlier sections of this review, metastasis is a non-random process and is 
dependent on intricate tumuor-stroma interactions in the target organ. Properties of circulating 
breast cancer cells and the microenvironment are imperative factors in organ-specific metastasis. 
Studies in model system using lung-tropic cells have focussed on the molecules that mediate the 
adhesion of cancer cells to the lung vascular endothelium. When the breast cancer cells arrive at the 
pulmonary capillaries, they can be physically trapped in the narrow blood vessels. The adhesion and 
extravasation of cancer cells to the lung is mediated by crosstalk between adhesion molecules on 
tumour cells and receptors on the endothelium. It was demonstrated that a transmembrane domain 
of metadherin is responsible in mediating the homing of breast cancer cells specifically to the lung, 
but not to other organs, by binding to an unknown receptor present in lung endothelium [227]. 
Metadherin is overexpressed in breast cancer tissue and tumour xenografts. Antibodies reactive to 
the lung homing domain of metadherin, inhibited breast tumour cells from forming experimental 
lung metastases, suggesting that metadherin mediates localization at the metastatic site [227]. Gene 
expression profiling has predicted lung metastasis gene signature and identified a set of genes that 
mediates breast cancer metastasis to lung and is clinically correlated with the development of lung 
metastasis when expressed in primary breast cancers [228, 229]. It is important to note that there is 
only a limited overlap between the genes involved in bone and lung metastasis signatures, indicating 
a discrete functional necessity for different organ-specific metastasis. It has been shown that ER 
positive luminal-like tumours display long latency periods and frequently colonize to bone, whereas 
ER negative tumours display a shorter course to metastasis development and frequently metastasize 
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to visceral organs [99, 100, 230, 231]. Her2 positive breast cancer is associated with increased risk of 
metastases to brain as compared to other subtypes. Metastatic breast carcinoma metastasis to CNS 
is common among patients receiving trastuzumab-based therapy, including patients responding to 
therapy outside the CNS [232, 233]. The molecular mechanisms involved in development of brain 
and liver metastases are not that well characterised. The highly restrictive structure of the blood 
brain barrier (BBB) poses a challenge to tumour cells for invasion into parenchyma and their growth 
as macro metastases. However, tumour cells take advantage of cytokines secreted by astrocytes such 
as IL-1, IL-3, IL-6, dE&ɲ͕ IGF-1, and PDGF-1 to stimulate their invasive and survival capabilities [234, 
235].  
 
7. Therapeutic implications  
As highlighted in this review, the microenvironment is actively involved in every step of breast cancer 
development and progression, thus providing numerous potential therapeutic targets. However, as 
demonstrated by the failure of anti-angiogenic agents in treatment of breast cancer, even targeting 
key microenvironmental hallmarks of cancer does not guarantee successful anti-tumour effects in 
humans and may be associated with widespread toxicities [236]. Although only a few agents that 
specifically target the environment are in routine clinical use in breast cancer, these benefit large 
numbers of patients.  
 
Among the most widely used drugs that act through modifying the microenvironment are aromatase 
inhibitors (AIs), agents that prevent generation of estradiol from androgens in peripheral tissues 
through aromatisation. AIs like letrozole, anastrazole and exemestane are used to treat ER+ve breast 
cancer in postmenopausal women, reducing estradiol to near undetectable levels and thereby 
depriving ER+ve tumour cells of a growth stimulatory signal [237]. These drugs are mainly used in the 
adjuvant setting, with a recent study reporting that prolonged treatment (up to 10 years) with AIs 
continues to provide benefit by reducing the risk of recurrence [238]. AIs also have the potential to 
prevent development of breast cancer; results from 2 large trials with 8,424 participants showed that 
AIs reduced ER+ve breast cancer incidence by 53% [20, 239]. Despite this major benefit, AIs are not 
yet widely used in the preventive setting, even for high risk women, possibly due to the associated 
side effects [240]. In addition to increased use as adjuvant therapy, a  large number of trials exploring 
the effects of AIs in combination with other agents are ongoing in breast cancer, including in the 
metastatic setting, hence their use is growing.  
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Bone-targeted agents (mainly anti-resorptive bisphosphonates, BPs) have long been in routine use to 
treat breast cancer-induced bone disease in the metastatic setting, resulting in improved quality of 
life but without prolonging overall survival [241]. In the adjuvant setting, BPs have recently been 
shown in a meta analysis of more than 18,000 patients to reduce bone recurrence and improve 
breast cancer survival, specifically for post menopausal women [242]. The mechanisms responsible 
for this positive effect on survival remains to be determined, but increased use of BPs in the adjuvant 
setting will undoubtedly save many lives in the coming decades. A large adjuvant trial (D-CARE, 
NCT01077154 ) of another bone-targeted agent, Denosumab, is due to report in 2018. In this trial, 
4,500 patients with early breast cancer have received Denosumab (an antibody to RANKL) or placebo 
for 5 years. This trial will determine whether targeting the osteoclast through inhibition of RANK-
RANKL interactions also affects survival of patients with early breast cancer, as has been established 
for adjuvant BPs.  
 
Perhaps the most promising development for microenvironmental targeting is the emerging use of 
immunotherapy, and we are only at the very beginning of harnessing the anti-tumourigenic power of 
the immune system. Breast tumours are generally not highly immunogenic although this differs 
between subtypes; triple negative BC is considered the most inflamed subtype whereas ER+ve 
tumours, in particular Luminal A, have a non-inflamed phenotype. A range of different approaches to 
breast cancer immunotherapy are currently under development, including checkpoint inhibitors, co-
stimulatory antibodies, vaccines and immunostiumulatory agents [243]. Increasing use of 
immunotherapy is likely to identify particular patient subsets with tumours exhibiting specific 
immunophenotypic characteristics which will be more or less sensitive to these agents. 
 
An additional microenvironment-targeting agent undergoing clinical trials in breast cancer is the anti-
diabetic drug metformin, which acts by reducing hepatic glucose production and has been suggested 
to have both direct and indirect anti-tumour effects [244]. The window of opportunity trial 
(NCT00897884) 39 non-diabetic women with breast cancer were given 500 mg metformin three 
times per day for approximately 2 weeks prior to surgery. Compared to the diagnostic biopsy,  there 
was decreased tumor expression of the insulin receptor, combined with a reduction in both PI3K and 
Ras-MAPK signaling, following metformin administration, suggesting that metformin has indirect, 
insulin-dependent anti-tumour effects [245]. Further trials of metformin in breast cancer are ongoing 
(>39 currently listed on ClinicalTrials.gov), including a large study comparing 5 years of adjuvant 
metformin to placebo in over 3,900 patients, aiming to establish whether this agent has the potential 
to improve disease free survival (NCT01101438), [246]. Due to complete in 2020, this trial will be 
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instrumental when it comes to the utility of metformin in the adjuvant setting in breast cancer, and if 
positive is likely to alter clinical practice to include this well-tolerated agent, which has the added 
advantage of preventing or delaying development of type 2 diabetes. 
 
Finally, there are a number of current clinical trials that aim to determine whether anti-angiogenic 
agents (mainly the VEGF-A inhibitor Bevacizumab) can be beneficial as part of combination therapy 
in specific breast cancer patient populations, despite their failure as single agents. It is therefore 
possible that targeting the tumour vasculature, a key component of the supportive 
microenvironment, may still turn out to demonstrate clinical efficacy in subgroups of breast cancer 
patients receiving  specific therapeutic regimens. 
 
8. Expert commentary  
 
A common theme throughout this review is the considerable heterogeneity within the tumour 
microenvironment, represented by a range of cell populations and subtypes, each with their 
different function in tumour development and progression. In many cases, we are not able to reliably 
differentiate between these sub-populations, in particular in human samples, hence mapping their 
presence as well as any changes induced by therapy is not yet feasible. There is increasing 
understanding that successful therapeutic targeting of the microenvironment relies on the 
elimination or promotion of specific population subtypes, this in turn requires the identification of 
subtype-specific markers that represent potential ͚ĚƌƵŐĂďůĞ͛ targets. It is evident that we still have a 
long way to go before effective, subpopulation-specific targeting becomes part of the standard anti-
cancer therapeutic arsenal. However, several highly effective agents targeting enzymes (aromatase 
inhibitors), specific cell types (osteoclast inhibitors) or cell populations (immunotherapy) are in 
routine clinical practise, with their use expected to increase over the coming decades. For example, a 
recent large (n=1,918) clinical trial showed that extension of adjuvant treatment with aromatase 
inhibitors beyond 5 years is beneficial for women with hormone-receptor positive early breast 
cancer, preventing disease recurrence compared to the placebo group [238]. As a result, the large 
number of patients currently taking AIs are likely to continue to do so for up to 10 years as opposed 
to the previously recommended 5 years. Likewise, a meta-analysis of adjuvant bisphosphonate (BP) 
trials demonstrate that post-menopausal women with early breast cancer (irrespective of hormone 
receptor status) have a survival benefit from adjuvant use of bone-targeted BPs [242]. With their 
capacity to benefit large patient populations, increased uptake and duration of microenvironment-
targeting AIs or BPs in the adjuvant setting has the potential to save many thousands of lives. 
Similarly, the myriad of ongoing clinical trials of immunotherapies in breast cancer will almost 
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certainly result in new therapeutic regimens that modify the immune component of the tumour 
microenvironment entering mainstream clinical practice. In breast cancer this will rely on our success 
in developing approaches that render the tumours more immunogenic and hence susceptible to 
immune attack. Inevitably, these new developments come with a number of caveats that may 
restrict their uptake; in the case of adjuvant BPs, the reason why only post-menopausal women have 
a survival benefit remains to be established, and the most potent agent (Zoledronic Acid) can only be 
administered as an IV infusion. AIs are associated with considerable side effects (joint and muscle 
pain, loss of bone mass), as are immunotherapies (mucositis, skin reactions, flu-like symptoms), and 
Zoledronic acid may cause osteonecrosis of the jaw in a small number of patients. However, the 
considerable clinical benefit gained from these agents, combined with increasing experience in how 
to manage their side-effects, is likely to outweigh the negative effects for patients.  
The majority of patients with breast cancer undergo surgery to remove the tumour within a few 
weeks of diagnosis, hence all subsequent therapy is aimed at potential disseminated disease rather 
than the primary tumour. It remains to be established to what extent agents that target the 
microenvironment modify cancer development beyond the primary tumour. However, it is important 
to note that agents targeting non-cancer cells will almost invariably be combined with drugs that 
directly target the tumour cells themselves, in order to maximise the anti-tumour effect through a 
two-pronged attack. As demonstrated by the effective drugs currently in clinical use, and with the 
potential of immunotherapy to revolutionise cancer treatment over the coming decades, targeting 
the microenvironment is now considered an intrinsic part of successful anticancer strategies.   
 
9. Five-year view 
The introduction of novel therapeutics/diagnostics in breast cancer is challenging due to the 
generally excellent survival for patients with organ-confined disease. Around 80% of patients are 
alive 5 years after diagnosis, hence clinical trials require long follow up periods and inclusion of large 
number of patients in order to show benefit beyond best current treatment. To address this, there is 
considerable research efforts focussed on selection of patient sub-groups and development of early 
surrogate markers reflecting outcome. This is particularly important with the increasing introduction 
of expensive novel agents (CDK inhibitors, immunotherapy), where identification of the patients 
most likely to benefit based on their primary tumour characteristics is essential. The use of ͚ǁŝŶĚŽǁ 
ƚƌŝĂůƐ͛ is increasing, allowing assessment of biological changes (and hence identification of potential 
surrogate markers of benefit) in the primary tumour caused by therapy given prior to surgery. 
However, the ultimate effect of novel agents or biomarkers will not be clear until impact on disease-
free survival is established, often decades later. How the components of the local tumour 
microenvironment impacts the response to therapy remains to be fully established, but in the case of 
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immunotherapy the number of tumour infiltrating immune cells (assessed prior to treatment) has 
been shown to be an important predictor of outcome. In the next five years we can expect the 
results from several clinical breast cancer trails of agents targeting the distal microenvironment. This 
includes D-CARE (NCT01077154), investigating the effects of the bone-targeted agent Denosumab in 
the adjuvant setting in over 4,500 patients. If positive, this trial will further establish that adjuvant 
therapy targeting the distal microenvironment (bone) improves breast cancer survival, in agreement 
with results from trials with adjuvant bisphosphonates. In addition, ClinicalTrials.gov lists more than 
130 immunotherapy trials in all stages of breast cancer, alone and in combination with current 
standard therapy (including radiotherapy and surgery). This includes checkpoint inhibitors, immune 
modulators, vaccines and adoptive T cell transfer therapy. Positive findings are likely to result in 
rapid changes in clinical practise, in particular in triple negative and metastatic breast cancer where 
outcome currently are poor and novel therapeutic options are urgently needed. 
 
10. Key issues 
ͻ Cellular and molecular components of the microenvironment play a role in breast cancer 
development, progression and in determining response to therapy. 
ͻ The microenvironment comprises a multitude of different elements, including cells, soluble 
factors and extracellular matrix components, both locally (in the breast) and distally (at 
metastatic sites).  
ͻ Modification of the microenvironment by factors released from the primary breast tumour 
may contribute to preparing the future metastatic site (the pre-metastatic niche), but evidence 
for this from human disease is lacking. 
ͻ Despite its importance, the presence/composition of microenvironmental components are not 
routinely assessed as part of breast cancer diagnosis or in therapeutic decision making.  
ͻ With the introduction of immunotherapy, clinical evaluation of the degree of immune 
infiltration in the primary tumour is increasingly considered in order to select patients most 
likely to benefit. 
ͻ Aromatase inhibitors are examples of therapeutics in routine use for large, heterogeneous 
groups of breast cancer patients that target the microenvironment rather than the primary 
tumour directly. 
ͻ Bone-targeted agents (bisphosphonates) have been shown to significantly improve survival of 
post menopausal women in the adjuvant setting, their use is likely to increase for this patient 
population. 
ͻ Targeting the microenvironment will benefit specific patient subgroups, reflecting the 
heterogeneous composition of breast tumours.  
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ͻ In all cases, agents targeting the microenvironment will be used in combination with standard 
therapy to maximise the effect on breast cancer progression. 
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